Pharvaris Q3 2026: Wider Loss as FDA Decision Nears
As seen on the 24/7 Wall St. homepage on November 12, 2026.
The wider loss is the cost of a launch build: general and administrative spending nearly doubled to $19.61 million as the company staffs up ahead of an April 23, 2027 FDA decision on oral deucrictibant. Cash of $313.94 million funds at least twelve months, but management says more financing is coming, so dilution is the live risk for a $2.4 billion pre-revenue biotech.
Continue ReadingShow less
Pharvaris posted a Q3 2026 loss per share of $0.74, missing expectations of $0.72. Revenue remained at zero, as it has every quarter, because the company's lead drug, deucrictibant, has not yet reached the market. The quarter's headline numbers are almost beside the point for a company whose entire investment case rests on what happens on April 23, 2027, when the FDA is due to issue its decision on deucrictibant IR for the on-demand treatment of hereditary angioedema attacks.
The earnings miss traced directly to a surge in general and administrative spending, which nearly doubled to $19.61 million from $10.94 million a year earlier. That money is going into building a commercial organization ahead of a potential 2027 launch. Research and development expenses also rose, to $36.00 million from $33.11 million, reflecting ongoing work on the extended-release formulation and a separate study in a related condition.
The quarter did deliver a meaningful clinical result. The pivotal CHAPTER-3 prophylaxis study met its primary and all secondary efficacy endpoints, with the mean monthly attack rate reduced 83% versus placebo. CEO Berndt Modig called it a major milestone and said the data addresses unmet needs across both on-demand and long-term prevention of bradykinin-mediated angioedema attacks. Results from CHAPTER-3 and other deucrictibant studies were set to be presented at the ACAAI Annual Scientific Meeting shortly after the filing.
Sponsored
Cash stood at $313.94 million, which management says is sufficient to fund at least twelve months of operations. The catch is that management also acknowledged additional financing will be required, and with 70.3 million weighted average shares already outstanding after a May 2026 equity offering, dilution is a live and acknowledged risk for a company valued at roughly $2.4 billion with no product revenue yet on the books.
The next hard catalyst beyond the April 2027 FDA decision is topline data from part one of the CREAATE study, which is evaluating deucrictibant XR for prophylaxis in a related angioedema condition, with results expected in the first quarter of 2027. A U.S. new drug application for the XR prophylaxis formulation is planned for the first half of 2027. Investors are essentially holding a binary position on a single regulatory outcome, with the spend curve rising steeply in every quarter between now and that verdict.
Mentioned: PHVS